The aberrant expression of tissue factor (TF) in acute promyelocytic leukemia (APL) cells has been implicated in the pathogenesis of the APL coagulopathy. In this study, we found that in APL patients receiving ATRA or As 2 O 3 treatment, the improvement in hypercoagulobility and hyperfibrinolysis paralleled the correction of plasma fibrinogen level and amelioration of bleeding symptoms. Notably, clinical improvement was also correlated to ATRA/As 2 O 3 -induced rapid decrease of membrane procoagulant activity (PCA) and TF contents of APL blasts. Consistent with the in vivo findings, the membrane PCA, TF antigen and its mRNA level within NB4 cells were rapidly down-regulated by 1 M ATRA or As 2 O 3 , while 0.2 g/ml DNR increased these TF parameters prior to its effect upon apoptosis induction. The down-regulation of TF mRNA by ATRA was partially de novo protein synthesis-dependent and at least partially attributed to a mechanism of destabilizing TF mRNA. On the other hand, in addition to its modulation on mRNA, As 2 O 3 could also induce an accelerated TF protein turnover. These distinct effects were corroborated with the properties of these agents in causing the degradation of PML-RAR␣ protein. All three therapeutic agents, however, enhanced the potential of NB4 cells to stimulate the expression of TF and PCA in endothelium. Taken together, our data suggest that the rapid and distinct regulation of TF on APL cells by these therapeutic agents might at least partially contribute to their effects on APL coagulopathy.
Introduction
Tissue factor (TF), an integral membrane glycoprotein, is expressed on a variety of cell types located out of vasculature under normal circumstances. [1] [2] [3] [4] [5] It has been well documented that TF serves as an initiator in some coagulation pathways via interaction with coagulation factor VII (F VII) and its activated form (F VIIa). 6, 7 In many pathological processes such as atherosclerosis, septic shock, and cancers, TF is often expressed at a relatively high levels by monocytes/ macrophages and endothelial cells, thereby initiate intravascular coagulation. 8, 9 In addition, TF is regarded as a member of class II cytokine receptor superfamily and may play a role other than that in coagulation. For example, TF abnormally expressed on tumor tissue can suppress the expression of thrombospondin-1 (TSP-1) which has inhibitory effects on tumor growth and angiogenesis, stimulates the production of vascular endothelial growth factor (VEGF), and potentiates the blood-borne metastasis in several melanoma and hepatic tumor cell systems. myeloid leukemia, has been attracting wide interest in biomedicine due to its two features. Firstly, most APL patients possess a reciprocal chromosome translocation t (15;17) , resulting in the generation of the PML-RAR␣ fusion proteins. 14 Secondly, all-trans retinoic acid (ATRA) can induce complete remission in most APL patients, which has become a successful model in differentiation-induction therapy in cancers. 15, 16 More importantly, APL is frequently accompanied with a serious bleeding syndrome, which is exacerbated by conventional chemotherapy in the early stage of treatment, leading to failure of remission induction. 17 Mechanisms underlying the bleeding diathesis in APL have been intensively investigated. 18 At least three different, but mutually inexclusive mechanisms have been proposed, that is, the activation of coagulation system, hyperfibrinolysis system and nonspecific proteolysis. 19 It has been well shown that cancer procoagulant (CP) and TF are abnormally expressed by APL cells. 20, 21 In addition to high TF level in APL cells, 22, 23 some reports showed that APL cellconditioned medium could induce the higher expression of TF in endothelial cells, which might be mediated by some APL cell-secreted cytokines such as IL-1␤. 24 Furthermore, procoagulant activity (PCA) of APL cells was mainly attributed to TF molecules while the CP only exerted a minimal influence. 25 Previous studies showed ATRA has dual behaviors in effects of ATRA on the modulation of TF. ATRA can decrease the level of TF antigen and PCA on APL cells in an in vitro culture after at least 24 h induction and antagonize the upregulating effect of NB4 cell-conditioned medium on the TF expression in vascular endothelium. 20, 24 However, ATRA potentiates the secretion of IL-1␤ by APL cells, the latter in turn indirectly increases the expression of TF in umbilical cord vein endothelium. 24 Recently, our clinical observation showed that differentiation/apoptosis induction of APL cells by As 2 O 3 unexpectedly relieves the occurrence and severity of DIC and bleeding symptoms during remission induction in a group of relapsed APL patients. This prompted us to carry out a detailed comparative study with regard to TF modulation in APL cells and endothelium exposed to ATRA, As 2 O 3 , and daunorubicin (DNR). The results revealed that distinct modulation of TF in both APL cells and vascular endothelium by ATRA, As 2 O 3 , and DNR may be related to their effects on bleeding syndrome in vivo through influencing coagulation activation.
Materials and methods

Patients and sample collection
Twenty-three consecutive APL patients, including 13 males and 10 females with their ages ranging from 14 to 54 years, entered this study. Twelve cases were newly diagnosed and 11 were firstly relapsed. Eleven of 12 primary patients were orally given ATRA in a dose of 20 mg/m 2 /day, while 11 relapsed and one primary patients were treated with intravenous drips of 10 ml 0.1% As 2 O 3 every day until complete remission. Samples from 20 sex-and age-matched normal individuals were used as controls for the examination of plasma parameters in the present study. 
Cell culture
Promyelocytic leukemia cell line NB4 cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL, Grand Island, NY, USA), 1 m sodium pyruvate, 100 U/ml of penicillin and streptomycin. Before exposure to the treatment of 1 m ATRA, 1 m As 2 O 3 or 0.2 g/ml DNR, the NB4 cell density was adjusted to 3-5 × 10 5 /ml and kept under density of 1 × 10 6 /ml during the whole incubation time. The viable cells were determined by trypan blue exclusion. The cell differentiation and apoptosis were evaluated by Nitroblue tetrazolium (NBT) reduction test and DNA ladder assay, respectively. Human umbilical vein endothelial cells (HUVEC) were digested with 0.1% collagenase 1 (Sigma, St Louis, MO, USA) and cultured according to the method described by Jaffe et al. 26 The HUVECs were seeded into 24-well culture plates at a cell density of 3 ×10 5 and cultured for 3 to 4 days before use until these cells reached complete confluence. Only primary endothelial cells were used in this study.
TF antigen examination
2 × 10 6 NB4 or fresh APL cells were collected, washed with pre-chilled PBS, and mixed with 250 l of pre-chilled 1% (v/v) Triton-X100/TBS (pH 8.5) 10 times, stirred for 1 min, and kept at 4°C for 30 min. The HUVEC lysates were obtained by treating the cells with 1% Triton-X 100/PBS at 4°C for 2 h. Thereafter, cells were centrifuged at 12 000 g for 20 min at 4°C. The supernatant was collected and stored at −80°C. 22, 25 The TF antigen levels in the supernatants or plasma were determined using an lmubind tissue factor ELISA kit purchased from American Diagnostica (Greenwich, CT, USA) and the total protein contents of extracts were measured using the BCA protein assay (Sigma). RNA extraction and quantitative RT-PCR for TF mRNA 27, 28 Total RNA of leukemia cells was extracted with Trizol reagent (Gibco BRL), and quantified with both electrophoresis and absorption values of RNA samples at 260 and 280 nm. For determining the TF mRNA content within the total RNA samples, a pair of PCR primers (5Ј GGATGTGAAGCA-GACGTACT3Ј and 5ЈGTGTAGAGATATAGCCAGGA3Ј) which covered a length of 535 bp from exon 3 to exon 6 of TF mRNA were used. 29 The PCR products were cloned into pGEM-T vector and its authenticity was confirmed by DNA sequencing. Based on this clone, a TF cDNA mutant serving as an internal control of PCR was artificially constructed by removing a region of 55 bp between two unique restriction enzyme sites (HpaI and EcoRI). Reverse transcription (RT)-PCR reactions were performed with the general methods. After 35 cycles of PCR amplification, 10 l products were run on 3% agarose gel and stained with EB. The TF mRNA content in each sample was semi-quantified by comparing the intensities of 535 bp band representing the endogenous TF mRNA with those of 480 bp band representing internal control.
Cyclohexamide inhibition of de novo protein synthesis and TF mRNA stability examination
30
NB4 cells were pre-treated with 10 g/ml cycloheximide for 1 h to block the de novo protein synthesis before exposure to 1 m ATRA, 1m As 2 O 3 or 0.2 g/ml DNR for 12-24 h, then total RNA was extracted and TF mRNA levels examined. To study the possible changes in TF mRNA stability induced by different treatments, actinomycin D was added to NB4 cells in a final concentration of 5 g/ml after a pre-exposure to different agents, then RNA was isolated at desired time points and analyzed by quantitative RT-PCR.
Immunofluoresence assay for PML-RAR␣/PML proteins
Freshly prepared cytospins with 50 l NB4 cells (1 × 10 5 /ml) were sequentially fixed with 2% paraformaldehyde at 4°C for 30 min, methanol at 4°C for 10 min, and blocked with 1% BSA/PBS at 37°C for 30 min. The cells were subsequently incubated with an anti-PML antibody at 37°C for 45 min. 31 The FITC-conjugated IgG was used as secondary antibody.
The infection of U937 cells with PML-RAR␣ cDNA harboring retrovirus
The long-form PML-RAR␣ cDNA was inserted into the retrovirus vector pMSCVpac under the downstream of 5Ј LTR to form the plasmid pMSCV-PML-RAR␣-pac, which was transiently transfected into the packaging cell Bosc 23 by calcium phosphate precipitation. Cultural supernatant of transfectedBosc 23 cells was harvested 48 h later, and used to infect the amphotropic packaging cell PA317, which was further screened with 2.5 g/ml puromycine for 2 weeks. Finally, the dilution of supernatant of PA317 cells was co-incubated with the U937 cells and screened with puromycin. The expression of PML-RAR␣ in positive clones was examined using both RT-PCR and immunoflourescence assay.
Results
Clinical investigation
The decrease of PCA, TF antigen and its mRNA in fresh APL blasts and the relief of bleeding during ATRA or As 2 O 3 treatment:
Our clinical experiences showed that the fresh bleeding stopped around 1 week and bleeding symptoms disappeared around 2 weeks after the onset of ATRA or As 2 O 3 treatment, which closely paralleled TF downregulation of APL blasts. As shown in Table 1 , with ATRA or As 2 O 3 treatment for 14 days when most of BM cells were still of APL blasts (92%-82%), PCA, TF antigen levels in fresh APL cells were decreased significantly to baseline or became undetectable. RT-PCR analysis showed that TF mRNA was also reduced in the fresh APL cells (data from two representative cases were shown in Figure 1 ). In addition, the membrane PCA of fresh APL cells was also predominantly F VII-dependent, as shown in in vitro studies (see below).
The changes of coagulation and fibrinolysis-related parameters in patients with ATRA or As 2 O 3 treatment:
The disappearance of bleeding symptoms seemed not to be related to the changes in peripheral platelet and white blood cell counts, nor to changes in plasma levels of TF molecule. In Table 1 The changes of TF antigen and PCA of BM mononuclear cells in patients with APL during the treatment with ATRA Compared with normal control, ***P Ͻ 0.001, **P Ͻ 0.01, *P Ͻ 0.05. Compared with before treatment,
Figure 1
Changes of TF mRNA of the bone marrow of two de novo patients with ATRA treatment and two relapsed cases with arsenic treatment were assessed by semi-quantitative RT-PCR assay. For each sample, three different amplification reactions with the same sample and serially diluted amounts (0.05 pg, 0.0025 pg, 0.0125 pg from right to left) of exogenous internal standard (pTF) were done. PCR products were run on a 3% agarose gel and stained with EB. In addition to the expected bands of 535 bp (endogenous TF mRNA) and 480 bp (pTF), a smaller band (375 bp) appeared, which was an exon5-minus fragment due to alternative splicing of TF mRNA revealed by DNA sequencing.
contrast, the clinical improvement was accompanied with obvious restoration of the plasma levels of fibrinogen, SFMC, D-dimers, plasminogen and ␣ 2 -Pl, indicating a relief of the DIC-related coagulopathy and/or the hyperfibrinolysis in ATRA or As 2 O 3 treated patients (Table 2 ). In spite of the upregulation of t-PA level with the administration of ATRA (P Ͻ 0.01), as also reported by Falanga et al, 24 the plasminogen level was normalized. The plasma level of PAI declined, perhaps due to the increased consumption by a high level of t-PA. The t-PA level in As 2 O 3 group was reduced ( Table 2 , P Ͻ 0.05). Table 2 The changes of plasma levels of hemostastic parameters and TF in the patients with APL during the treatment with ATRA or As 2 31, 32 In this study, we showed that 0.2 g/ml DNR, a chemotherapeutic agent, did not induce the differentiation (Figure 2a) , but potently decreased cell viability (Figure 2b ) and induced apoptosis in NB4 cells, which was confirmed by DNA ladder examination ( Figure 2c) .
Data on NB4 cells
As shown in Figure 3 (upper panel), the TF antigen levels in NB4 cells were progressively downregulated by 1 m ATRA and 1 m As 2 O 3 with somewhat different patterns. 1 m ATRA rapidly and significantly decreased the TF antigen levels within 6 h after treatment, while the effect of 1 m As 2 O 3 was relatively slower, though also steady, reaching a level near the baseline at 72 to 96 h after treatment. In contrast with ATRA and As 2 O 3 TF antigen levels in NB4 cells rose gradually in the early phase of DNR treatment, reached a level of 450 pg/10 5 cells at 24 h after treatment, as compared to 300 pg/10 5 cells in the control group. Of note, significant changes in TF antigen levels had happened before the advent of significant cell death (with a cell viability around 80%). In addition, TF antigens within 5 × 10 5 /ml cell-derived cultural supernatants were 25.1, 4.5, 8.8 and 30.6 pg for control, 48 h treatment with ATRA, As 2 O 3 and DNR respectively, near to 1/10 of intracellular levels. In addition, ATRA could significantly and rapidly upregulate TM antigen levels in NB4 cells, which is consistent with a previous report. 20 However, no effects of As 2 O 3 on TM expression were seen (Figure 3 , middle panel).
As described above, it was reported that PCA of NB4 cell lysates was mainly dependent on cellular TF contents, especially the ratio of TF/TM antigens on cell membrane. 22, 25 Recent data showed that the multimerization of TF proteins affected PCA of TF in HL-60 cells to a great extent. In this study, we used one-stage clotting assay with different types of plasma (PNHP, FVIID and FVIIID) to examine the PCA of NB4 cells with or without different treatments (Figure 3) . The results showed that changes in the recalcification times detected with FVIID during the treatment were longer than those seen with the PNHP and FVIIID. This indicates the changes in the PCA is FVII-dependent (data not shown). Furthermore, the modulations of PCA levels in different groups were roughly correlated with that of TF antigens, with a lag of about 24 h for PCA in its kinetics. The PCA values of cultural supernatants were lower, near to baseline (data not shown). These data suggested PCA were F VII-dependent and TF had a major role in determination of the PCA of APL.
Mechanisms of ATRA, As 2 O 3 and DNR-modulated TF antigens
ATRA, As 2 O 3 and DNR induced-TF antigen alteration may be either due to changes in its biosynthesis, its turnover rate, protein shedding or releasing process. In answer to this question, the TF mRNA levels were semi-quantified by means of a competitive RT-PCR including an internal control of artificial TF cDNA mutant. The results showed that ATRA or As 2 O 3 treatment led to progressive decline of mRNA levels in a kinetic parallel to changes in antigen levels (Figure 4a ), suggesting that ATRA or As 2 O 3 induced the reduction in biosynthesis of TF antigens. A relatively higher level of TF gene mRNA existed in cells with As 2 O 3 treatment for 48 to 96 h as compared to ATRA-treated cells, while TF antigen levels were virtually the same in cells treated by two different drugs, suggesting in addition to its synthesis changes, As 2 O 3 -induced acceleration of TF protein turnover rate could also contribute to its modulation on TF antigens. The TF mRNA levels in DNR-treated cells were elevated at 6 and 12 h after treatment. The cyclohexamide (CHX) inhibition test of de novo protein synthesis showed that CHX treatment suppressed the downregulation effect of ATRA on the NB4 cells TF expression, in that the 480 bp band (exogenous internal control TF DNA) was weaker in CHX + ATRA treatment than in ATRA treat- ment, which indicated that endogenous TF mRNA level was higher in CHX + ATRA treatment than in ATRA treatment. This implies that TF mRNA down-regulation of NB4 cells by 1 m ATRA was accomplished at least partially via an indirect way, dependent on de novo protein synthesis (Figure 4b ). The actinomycin D inhibition test revealed that the half-life of TF mRNA in ATRA-treated NB4 cells was shortened to about 30 min from around 60 min in untreated NB4 cells, indicating that mRNA destabilizing mechanism was involved in TF regulation process mediated by ATRA (data not shown).
The roles of PML-RAR␣ fusion proteins in ATRA, As 2 O 3 and DNR-modulated TF antigens:
To investigate the possible roles of PML-RAR␣ fusion proteins in TF expression and its modulation by ATRA, As 2 O 3 and DNR, the PML-RAR␣-expressing U937 clones were used as the in vitro model. It was found that the TF antigen contents in PML-RAR␣ + U937 cells were significantly higher than that in U937 cells infected with vector retrovirus (Figure 5a , P Ͻ0.01), though not to an extent estimated according to the TF content difference between NB4 cells and U937 cells. 22 The TF contents were down-regulated by the 1 m ATRA regardless of PML-RAR␣ transfection (Figure 5a) .
Furthermore, subcellular distribution of PML-RAR␣ proteins was examined with anti-human PML antibody. As shown in Figure 5b , PML-RAR␣/PML distribution in NB4 cells with DNR treatment for 24 and 48 h was exactly the same as that in untreated NB4 cells, which presented a micropunctated pattern. This is significantly different from ATRA-or As 2 O 3 -treated NB4 cells, in which the PML-RAR␣/PML proteins were restored to the few speckle-like distribution pattern or disappeared (data not shown). 32 
Data on HUVEC
With respect to the TF-associated coagulopathy in APL and its evolution under different therapeutic agents, changes in PCA and TF antigen level in vascular endothelium also have to be considered. 19 In this study, TF and PCA were tested on HUVECs treated with 1 m ATRA, 1 m As 2 O 3 and 0.2 g/ml DNR, as well as NB4 cell culture supernatants with the corresponding treatment. After 4-h incubation in vitro, 1 m ATRA mildly downregulated the levels of both PCA and TF antigen, as shown by other researchers, and the effects of 1 m As 2 O 3 or 0.2 g/ml DNR were trivial. However, 48 to 96 h treatment of NB4 cells by these agents potently enhanced the potential of their cultural supernatants to stimulate the expression of TF and PCA by HUVEC (Figure 6) , with 48 h treatment by DNR having the strongest effect on TF antigen level (P Ͻ 0.05).
Discussion
A complicated picture has emerged from a number of studies regarding the hemostatic abnormalities underlying the bleeding syndrome in APL patients, and the relative weight of each abnormality as the possible causes have been evaluated through analyzing the hemostatic parameter changes accompanying the administration of ATRA. 18, 19 In our observation including 11 primary patients receiving ATRA, the correcting rates of both coagulant and fibrinolysis parameters, such as SFMC, plasminogen, ␣ 2 -PI and fibrinogen seemed to closely parallel the relieving and disappearance of bleeding syndrome, and d-dimer also decreased significantly within the first 2 weeks. The up-regulation of t-PA did not prevent the improvement of plasminogen and fibrinogen. The bleeding a c b symptoms disappeared before the obvious restoration of peripheral platelet counts and reduction of leukemia cell mass, although it is generally accepted that the thrombocytopenia certainly play a role in the bleeding occurrence in leukemia.
It is interesting to compare the hemostatic parameter changes induced by As 2 O 3 with those by ATRA. Although they induce complete remission in APL with distinct mechanisms, they result in a rapid correction of coagulopathy. In this study, we showed that As 2 O 3 administration in 12 relapsed patients, who had a similar hemostatic abnormality to that in primary patients receiving ATRA treatment, caused similar improvement of hemostatic parameters to that by ATRA. The only exception was in the changes of t-PA and PAI, which were improved within the first 2 weeks in the As 2 O 3 group but not in ATRA-treated series (Table 2) . These results supported the view that ATRA or As 2 O 3 -induced rapid amelioration of bleeding diathesis may involve the improvement or correction in both coagulation activation and hyperfibrinolysis. It remains to be explained why a significant rise in t-PA or decrease in PAI in the ATRA group did not affect the overall restoration of fibrinogen, plasminogen and ␣ 2 -PI.
Among several feasible hemostatic changes responsible for the amelioration of bleeding syndrome, we first demonstrate that As 2 O 3 induces a rapid and significant loss of membrane PCA and TF contents of APL blasts in a similar rate as ATRA does, and TF has a pivotal role in determining PCA in APL cells. Of note, the amelioration of bleeding symptoms paralleled only the loss of PCA and TF in APL blasts, but not TF molecules present in plasma in our observation. These data were confirmed in NB4 cells. 1 m As 2 O 3 progressively downregulated the membrane PCA, the TF contents and the mRNA levels of TF gene in NB4 cells. Interestingly, TF antigen had decreased significantly before the appearance of obvious apoptosis indicated by DNA ladder at 12 h after exposure to As 2 O 3 (Figure 2c ). On the other hand, ATRA-induced decrease of TF antigens seemed to parallel the decrease of its mRNA level. However, As 2 O 3 -induced reduction of the TF mRNA was not as deep as that in ATRA, in contrast to the TF protein changes, suggesting that As 2 O 3 could also trigger TF protein degradation. In addition, the downregulation of TF mRNA by ATRA required the de novo protein synthesis at least partially, and this was at least partially caused by a shorterning of the half-life of TF mRNA. The reason that the decrement of PCA seemed to be later compared to that of TF antigen could be double: (1) the relatively longer T 1/2 life for membrane TF molecules. The diminution of TF antigen in the early phase mainly reflected a reduction of the cytoplasmic TF storage resulting from a decreased synthesis and/or accelerated degradation. (2) Some unidentified procoagulant factors exist on the membrane of NB4 cells which may be resistant to ATRA or As 2 O 3 in the early phase, compensating PCA for the TF loss. During the 24-48 h of treatment, the membrane PCA in As 2 O 3 group
Figure 6
Direct effects of ATRA, As 2 O 3 and DNR treatment and the various conditioned media from different agent-treated NB4 cells on the TF levels and PCA of human umbilical vein endothelial cells (HUVEC). NB4 cells were treated with the agents for 48 and 96 h, and their supernatants, after adjustment of concentrations for cell densities, were harvested and added into HUVEC for 4 h. was higher than that in the ATRA group. It may be related to a finding that As 2 O 3 was unable to upregulate the expression of thrombomodulin (TM) (Figure 3 ). The upregulation of TM in NB4 cells by ATRA has been reported by Koyama et al. 20 One implication from these data could involve the 'release theory'. It is suggested that DIC in APL results from the release of procoagulants from the abnormal promyelocytes accompanying the cell senescence and chemotherapyinduced cell lysis. Based on this, the reason for the amelioration of DIC by ATRA was initially attributed to its differentiation-inducing mechanism by which it reduces the mass of neoplastic promyelocyte without provoking cell lysis. Lately, ATRA was reported to be able to regulate the procoagulant activity of APL cells both in vivo and in vitro. In fact, TF in APL cells could be expressed as a membrane receptor for F VII or F VIIa, so they could impart procoagulant activity to living APL cells. In this study, we found that in vivo membrane procoagulant activity and TF significantly decreased within the first 2 weeks of ATRA or As 2 O 3 treatment with the disappearance of bleeding symptoms, when APL blasts in BM still remained at a high level. At the same time, low levels of TF were detected in the supernatant of NB4 cells, and plasma TF level was not reduced in the initial 2 weeks of treatment. Therefore, amelioration of DIC in vivo after ATRA and As 2 O 3 administration may mainly result from the rapid reduction of leukemia cell membrane PCA.
One interesting finding in our study is the rapid upregulating effect of the chemotherapeutic agent DNR on TF expression of NB4 cells in vitro, which preceded the apoptosis of NB4 cells induced by the drug. Though the molecular mechanisms mediating such effects are obscure at present, this phenomenon may contribute to the reported exacerbation of conventional chemotherapy such as DA regimen on DIC in APL, in addition to the plausible release of procoagulants resulting from cells death. DNR is one member of the anthracycline family, which is thought of as a stabilizing a complex between DNA and enzyme topoisomerase II. Another anthracycline, doxorubicin, was reported to increase the TFassociated membrane PCA of HL-60 cells in an in vitro culture system. 33, 34 In addition to their role as the procoagulant particles described above, APL cells have been found to secrete cytokines such as IL-1␤ into plasma, which in turn stimulate the TF and membrane PCA production on vascular endothelium. Indeed, we showed that like ATRA, 24 As 2 O 3 and DNR enhanced the potential of NB4 cell cultural supernatant to stimulate the TF and PCA expression of HUVEC. The clinical implication of enhanced TF and PCA expression on endothelium by these agents needs further investigation.
It is interesting to consider why As 2 O 3 , like ATRA, is able to progressively down-regulate the mRNA level of TF, though it seemed to be somewhat slower in vitro, and why the hemostatic changing pattern induced by As 2 O 3 looks so similar to that induced by ATRA in vivo (Tables 1 and 2 ). Recent work by Shibakura et al 28 showed that the downregulation effect of ATRA on TF mRNA in NB4 cells was mediated via both RAR␣ and RAR␤ nuclear receptors, and it may imply that the existence of unique fusion protein PML-RAR␣ probably involves the aberrant expression of TF in NB4 cells through its welldemonstrated dominant negative effects on wild-type RAR␣, 35 as supported by our result ( Figure 5 ). The practical mechanism may also involve the AP-1 sites located within the −172 to −227 region of TF gene, which have been shown to mediate the LPS-induced TF expression in THP-1 cells, 36 for Vallian et al 37 recently reported that both PML and PML-RAR␣ enhanced the AP-1-mediated transcription activity and this modulation by PML-RAR␣, but not PML, was abrogated by addition of ATRA. If so, the degradation of PML-RAR␣ induced by As 2 O 3 will relieve the suppression on the RA pathway executed by wild-type RAR␣ at endogenously physiological concentration of RA, 38 and abolish the stimulating effect of fusion protein on AP-1 pathway, which in turn lead to the down-regulation of TF mRNA. In contrast, DNR was unable to trigger the degradation of PML-RAR␣ fusion protein ( Figure  5b) . Hence, the normal RA pathway may remain repressed whereas the AP-1 activation continues, so that no downregulation of TF expression can occur. Recently, the leukemogenic role of PML-RAR␣ in APL has been directly demonstrated in transgenic mouse models established by several independent groups. In one model, transgenic mice with APL-like phenotype displayed the bleeding tendency and developed the pulmonary vessel thrombosis. 39 It is interesting to further approach this problem more directly in cell transfection tests and transgenic animal models of PML-RAR␣.
